1. Home
  2. ABEV vs NTRA Comparison

ABEV vs NTRA Comparison

Compare ABEV & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ambev S.A.

ABEV

Ambev S.A.

HOLD

Current Price

$3.04

Market Cap

47.7B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$277.78

Market Cap

39.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABEV
NTRA
Founded
1885
2003
Country
Brazil
United States
Employees
39606
N/A
Industry
Beverages (Production/Distribution)
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7B
39.1B
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
ABEV
NTRA
Price
$3.04
$277.78
Analyst Decision
Sell
Strong Buy
Analyst Count
4
15
Target Price
$2.94
$259.07
AVG Volume (30 Days)
24.9M
1.6M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
4.93%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$7.96
$18.08
Revenue Next Year
$5.35
$19.65
P/E Ratio
$16.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$131.81
52 Week High
$3.45
$288.04

Technical Indicators

Market Signals
Indicator
ABEV
NTRA
Relative Strength Index (RSI) 41.70 66.39
Support Level $2.84 $186.96
Resistance Level $3.07 $288.04
Average True Range (ATR) 0.07 10.93
MACD -0.01 -0.91
Stochastic Oscillator 12.50 69.79

Price Performance

Historical Comparison
ABEV
NTRA

About ABEV Ambev S.A.

Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: